Monte Rosa Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
321 Harrison Ave Ste 900, Boston, Massac...Phone Number
(617) 949-2643Website
www.monterosatx.comRevenue
$28.7 MillionStock Symbol
GLUEIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Monte Rosa Therapeutics
Founded in 2018 and based out of Boston, MA, Monte Rosa Therapeutics is a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically-relevant proteins.Explore more
Monte Rosa Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
LC
Senior VP, Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Monte Rosa Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Monte Rosa Therapeutics
Funding: Get notified immidiatlly once Monte Rosa Therapeutics has new funding data
Click to see if Monte Rosa Therapeutics had a recent Job posting/layoffs
Check out if Monte Rosa Therapeutics is spiking on competitors!
Monte Rosa Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Monte Rosa Therapeutics launches new products
Check if Monte Rosa Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Monte Rosa Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Monte Rosa Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Monte Rosa Therapeutics
Compare insights from companies similar to Monte Rosa Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Monte Rosa Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Monte Rosa Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Monte Rosa Therapeutics.
Monte Rosa Therapeutics financials insights
Gather financial insights about Monte Rosa Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$32.5M
Series B
$96M
2021
Series C
$95M
Share Placement
$222.3M
Monte Rosa Therapeutics Tech Stack
A closer look at the technologies used by Monte Rosa Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Stake & Stock Ownership, Finance
Hiring Plans
Monte Rosa Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Early Phase Clinical Trials, Pharmaceuticals, Medical Coding, Clinical Research, Medidata Rave, Health Sciences, and Biotechnology.
Hiring Plans
Project
Monte Rosa Therapeutics is planning the GFORCE-2 Phase II study in patients with cardiovascular or atherosclerotic risk, featuring three-month administration with a potential three-month extension and exploratory endpoints including liver inflammation, liver fat, anemia, weight loss, and A1C, with a strategy of targeting a higher-risk population to reduce study size and accelerate time to event toward Phase III readiness for atherosclerosis.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Clinical Operations
Monte Rosa Therapeutics News & Media
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Monte Rosa Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2018 and based out of Boston, MA, Monte Rosa Therapeutics is a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically-relevant proteins.... Read More
